CN106540119B - Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic - Google Patents
Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic Download PDFInfo
- Publication number
- CN106540119B CN106540119B CN201510629882.2A CN201510629882A CN106540119B CN 106540119 B CN106540119 B CN 106540119B CN 201510629882 A CN201510629882 A CN 201510629882A CN 106540119 B CN106540119 B CN 106540119B
- Authority
- CN
- China
- Prior art keywords
- parts
- compound wood
- root
- drug
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 53
- 239000002023 wood Substances 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 230000000202 analgesic effect Effects 0.000 title abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 47
- 208000002193 Pain Diseases 0.000 claims abstract description 41
- 230000036407 pain Effects 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 244000298479 Cichorium intybus Species 0.000 claims abstract description 10
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 10
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims abstract description 9
- 240000004784 Cymbopogon citratus Species 0.000 claims abstract description 9
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims abstract description 9
- 244000179525 Dracocephalum moldavica Species 0.000 claims abstract description 9
- 235000010700 Dracocephalum moldavica Nutrition 0.000 claims abstract description 9
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 9
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 9
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 9
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 9
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 9
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 9
- 240000007926 Ocimum gratissimum Species 0.000 claims abstract description 9
- 240000004760 Pimpinella anisum Species 0.000 claims abstract description 9
- 235000012550 Pimpinella anisum Nutrition 0.000 claims abstract description 9
- 240000000530 Alcea rosea Species 0.000 claims abstract description 8
- 235000017334 Alcea rosea Nutrition 0.000 claims abstract description 8
- 235000017303 Althaea rosea Nutrition 0.000 claims abstract description 8
- 244000090896 Nigella sativa Species 0.000 claims abstract description 8
- 240000005523 Peganum harmala Species 0.000 claims abstract description 8
- 235000008541 fennel flower Nutrition 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 235000005126 Peganum harmala Nutrition 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- -1 oral solution Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 210000004185 liver Anatomy 0.000 abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Abstract
It is molecular by fennel root skin, peganum harmala L, anise fruit, chamomile, Herba Apii graveolentis root, witloof, fennelflower seed, cichory root, lemongrass, Dracocephalum moldavica, Radix Glycyrrhizae, basil fruit and hollyhock that the invention discloses a kind of its pharmaceutical compositions of compound wood Ni Zi preparing the purposes in analgesic, its pharmaceutical composition of the compound wood Ni Zi.Gained drug can be efficiently applied to the treatment of pain, and have preferable therapeutic effect, in particular, having significant inhibiting effect, also, the of a tightly knit structure of the drug, compatibility are precise and appropriate, burden of liver is small, and toxic side effect is small to central and periphery property pain.
Description
Technical field
The present invention relates to pharmaceutical fields, and in particular, to a kind of its pharmaceutical composition of compound wood Ni Zi is preparing antalgesic
Purposes in object.
Background technique
Pain is one kind offending supervisor's feeling related with tissue damage or potential tissue damage and emotional experience.Perhaps
Simultaneously all along with pain, pain is still to perplex the FAQs of patient for the generation of more diseases.It is estimated that at least 30%
Individual will receive the torment of pain at its certain moment in life, and in these individuals, pain lasts one day or more
People accounts for 10%-40%.The disease incidence of global chronic ache accounts for the 7% to 40% of population.About 50%-60% suffers from chronic ache
Individual due to pain and temporarily or permanently partially or completely incapacitation.
Therefore, the research of analgesic is the emphasis of always study of pharmacy.
Summary of the invention
The present invention is directed at least solve one of the technical problems existing in the prior art.For this purpose, it is an object of the invention to
It is proposed that a kind of its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic, which can effectively treat pain.
It should be noted that the present invention is the following work based on inventor and completes:
Antipyretic-antalgic anti-inflammatory agent using morphine as the narcotic analgeiscs of representative and using aspirin as representative is releasing trouble
Person's pain aspect has played great function, but cannot be controlled effectively there are also pain quite a lot, while these two types of towns
The adverse reaction of pain medicine also can not be ignored.Morphine can be such that peripheral blood vessel expands, generation orthostatic hypotension, inhibition respiratory center,
Inhibit cough reflex, serious respiration inhibition that breathing can be caused to stop.Nausea and vomiting, constipation, abdominal discomfort, abdominal pain, gallbladder can be caused to twist
The reaction of the enteron aisles such as pain, causes the symptoms such as oliguresis, frequent micturition, urgent urination, dysuria, the retention of urine to urinary system, and have additive
Risk.Disease of digestive system, kidney and liver injury, shadow can often be caused by the antipyretic-antalgic anti-inflammatory agent of representative of aspirin
It rings blood routine and causes cardiovascular and cerebrovascular unexpected.These side effects limit the long-term use of drug, influence the clinical application of drug.
Its particle of compound wood Ni Zi is tradition dimension medicine, clinically mainly used for treating acne, eczema, chloasma, pelvic cavity
Inflammatory disease sequelae, the proliferation of mammary gland, nettle rash.Application No. is 201310218671.0 patents -- dimension medicine compound wood Ni Zi its
Application of the extract in terms of preparation promotes small bowel peristalsis drug discloses its extract of compound wood Ni Zi in preparation and promotes small intestine
Application in terms of wriggling drug has essential distinction with the present invention.
Inventor has studied the therapeutic effect of a large amount of compound wood Ni Zi its particle in all kinds of inflammation, in research ratio repeatedly
Centering is it was unexpectedly observed that its particle of compound wood Ni Zi has analgesic activity.In particular, having significantly to central and periphery property pain
Inhibiting effect, also, the pharmaceutical composition is of a tightly knit structure, compatibility is precise and appropriate, and burden of liver is small, and toxic side effect is small.
Thus, in one aspect of the invention, the invention proposes its pharmaceutical compositions of compound wood Ni Zi to ease pain in preparation
Purposes in drug.According to an embodiment of the invention, its pharmaceutical composition of the compound wood Ni Zi includes: fennel root skin, camel
Fluffy son, anise fruit, chamomile, Herba Apii graveolentis root, witloof, fennelflower seed, cichory root, lemongrass, Dracocephalum moldavica, Radix Glycyrrhizae, basil fruit and
Seed of hollyhock.
As a result, according to an embodiment of the invention, gained drug can be efficiently applied to the treatment of pain, and have preferable
Therapeutic effect has a significant inhibiting effect in particular, to central and periphery property pain, also, the drug it is of a tightly knit structure, match
5 is precise and appropriate, and burden of liver is small, and toxic side effect is small.
In addition, its pharmaceutical composition of compound wood Ni Zi according to the above embodiment of the present invention is preparing the use in analgesic
Way can also have the following additional technical features:
In some embodiments of the invention, its pharmaceutical composition of the compound wood Ni Zi is by following raw material medicaments weight proportion
Composition: 50-150 parts of fennel root skin, 50-150 parts of peganum harmala L, 50-150 parts of anise fruit, 30-80 parts of chamomile, Herba Apii graveolentis root 30-
80 parts, witloof is 30-80 parts sub-, 30-80 parts of fennelflower seed, 30-80 parts of cichory root, 30-80 parts of lemongrass, Dracocephalum moldavica are 30-80 parts sub-,
30-80 parts of Radix Glycyrrhizae, 30-80 parts of basil fruit and 30-80 parts of seed of hollyhock.The of a tightly knit structure of the drug, compatibility are precise and appropriate as a result, liver
Bear small, toxic side effect is small.
In some embodiments of the invention, the bulk pharmaceutical chemicals weight proportion composition are as follows: 120 parts of fennel root skin, harmel
Son 120 parts, 120 parts of anise fruit, 60 parts of chamomile, 60 parts of Herba Apii graveolentis root, witloof son 60 parts, 60 parts of fennelflower seed, 60 parts of cichory root,
60 parts of lemongrass, 60 parts of Dracocephalum moldavica, 60 parts of Radix Glycyrrhizae, 60 parts of basil fruit and 60 parts of seed of hollyhock.The drug ratio is proper as a result, association
Same-action is more obvious, more preferably to the therapeutic effect of pain.
In some embodiments of the invention, the dosage form of the drug is selected from injection, tablet, granule, syrup, glue
One of wafer, pill, oral solution, aerosol and spray.As a result, convenient for different according to administration object, using different agent
Type, to improve the flexibility of the drug.
In some embodiments of the invention, its pharmaceutical composition of the compound wood Ni Zi is with its particle of compound wood Ni Zi
Form provide.Existing Chinese patent drug is utilized as a result, can treat pain, also, the good effect of drug, toxic side effect are small.
Additional aspect and advantage of the invention will be set forth in part in the description, and will partially become from the following description
Obviously, or practice through the invention is recognized.
Detailed description of the invention
Above-mentioned and/or additional aspect of the invention and advantage will become from the description of the embodiment in conjunction with the following figures
Obviously and it is readily appreciated that, in which:
Fig. 1 shows in analgesic experiment according to an embodiment of the invention, its Granules on Mouse writhing of compound wood Ni Zi
The influence result of writhing number in latent 15min；
Fig. 2 shows in analgesic test according to an embodiment of the invention, its particle different time sections of compound wood Ni Zi
On mouse pain domain influence as a result,
Wherein, blank control group (Control), aspirin (Aspirin, 0.1g/kg) group, its particle of compound wood Ni Zi
(7.2,2.4,0.8g/kg) group, wooden Buddhist nun's particle abbreviation represents its particle of compound wood Ni Zi in the present invention.
Specific embodiment
The embodiment of the present invention is described below in detail.The embodiments described below with reference to the accompanying drawings are exemplary, only
It is used to explain the present invention, and is not considered as limiting the invention.
According to an aspect of the present invention, the present invention provides a kind of its pharmaceutical compositions of compound wood Ni Zi eases pain in preparation
Purposes in drug.According to an embodiment of the invention, its pharmaceutical composition of compound wood Ni Zi includes: fennel root skin, harmel
Son, anise fruit, chamomile, Herba Apii graveolentis root, witloof, fennelflower seed, cichory root, lemongrass, Dracocephalum moldavica, Radix Glycyrrhizae, basil fruit and another name for Sichuan Province
Certain herbaceous plants with big flowers.Inventors have found that gained drug can be efficiently applied to the treatment of pain, and there is preferable therapeutic effect, in particular, right
Central and periphery property pain have significant inhibiting effect, also, the of a tightly knit structure of the drug, compatibility are precise and appropriate, burden of liver
Small, toxic side effect is small.
According to one embodiment of present invention, when in clinical application, its pharmaceutical composition of the compound wood Ni Zi is used
When analgesia, its pharmaceutical composition of the compound wood Ni Zi of therapeutically effective amount is given to administration object, treatment can also be had
Its pharmaceutical composition of compound wood Ni Zi of effect amount is provided as the active constituent of drug, namely giving to object is wanted includes that treatment has
The drug of its pharmaceutical composition of the compound wood Ni Zi of effect amount.
It should be noted that term as used herein " therapeutically effective amount ", which refers to, is enough to show significant patient's benefit
The total amount of each active component at place.When using separate active ingredients for separate administration, which only refers to the ingredient.When combination is answered
Used time, the term then refer to the combined amount for regardless of combination, sequential or simultaneous administration all causing the active constituent of therapeutic effect.
In the sense of being compatible with the other ingredients of the formulation and harmless to its recipients, carrier, diluent or excipient must be
It is acceptable.
When the compound wood Ni Zi its pharmaceutical composition is used to ease pain, in general, its pharmaceutical composition of compound wood Ni Zi is logical
Any conventional application method for crossing the substance for playing similar effectiveness is administered with therapeutically effective amount.Suitable dosage range takes
Certainly in many factors, such as age and the relative health, compound used therefor of the seriousness of treated disease, subject
The preference and experience of effect, the approach of application and form, application targeted indication and related medical practitioner.Treatment institute
The those of ordinary skill for stating disease areas can determine that use by personal knowledge and disclosure of this application without excessive experiment
In the therapeutically effective amount of the compounds of this invention of given disease.Thus, it is possible to guarantee analgesia therapy effect.
According to one embodiment of present invention, its pharmaceutical composition of compound wood Ni Zi can be by following raw material medicaments weight proportion
Composition: 50-150 parts of fennel root skin, 50-150 parts of peganum harmala L, 50-150 parts of anise fruit, 30-80 parts of chamomile, Herba Apii graveolentis root 30-
80 parts, witloof is 30-80 parts sub-, 30-80 parts of fennelflower seed, 30-80 parts of cichory root, 30-80 parts of lemongrass, Dracocephalum moldavica are 30-80 parts sub-,
30-80 parts of Radix Glycyrrhizae, 30-80 parts of basil fruit and 30-80 parts of seed of hollyhock.The of a tightly knit structure of the drug, compatibility are precise and appropriate as a result, liver
Bear small, toxic side effect is small.
Still another embodiment in accordance with the present invention, bulk pharmaceutical chemicals weight proportion group can be with are as follows: 120 parts of fennel root skin, harmel
Son 120 parts, 120 parts of anise fruit, 60 parts of chamomile, 60 parts of Herba Apii graveolentis root, witloof son 60 parts, 60 parts of fennelflower seed, 60 parts of cichory root,
60 parts of lemongrass, 60 parts of Dracocephalum moldavica, 60 parts of Radix Glycyrrhizae, 60 parts of basil fruit and 60 parts of seed of hollyhock.The drug ratio is proper as a result, association
Same-action is more obvious, more preferably to the therapeutic effect of pain.
According to still another embodiment of the invention, the dosage form of the drug can be for selected from injection, tablet, granule, sugar
Starch one of agent, capsule, pill, oral solution, aerosol and spray.As a result, convenient for different according to administration object, using not
Same dosage form.For example, tablet, granule, syrup, capsule and oral solution or pill can be used for the ease of administration, and
And the dosage form of drug can be adjusted, according to the absorption site of drug and the release demand of drug to improve drug
Bioavilability extends the release time of drug.For serious patient, injection can be used, and then realizes large dosage
Administration requirements, also, avoid influence of the gastrointestinal circulation to medicament effective component.
According to a particular embodiment of the invention, its pharmaceutical composition of compound wood Ni Zi can be with its particle of compound wood Ni Zi
Form provide.Existing its particle of commercially available dimension medicine compound wood Ni Zi is utilized as a result, can treat pain, meanwhile, relative to
The drug of existing some treatment pain, the therapeutic effect of the drug is good, in particular, having to central pain and periphery property pain
Significant inhibiting effect, also, the toxic side effect of the drug is small.
Below with reference to specific embodiment, the present invention will be described, it should be noted that these embodiments are only explanation
Property, and be not considered as limiting the invention.
Embodiment
1, experimental material
Animal: KM mouse 80, SPF grades, 18~22g of weight, half male and half female, by Shanghai Univ. of Traditional Chinese Medicine experimental animal
The heart provides, animal credit number: SYXK (Hunan) 2009-0069.
Instrument: hot-plate instrument, pure water meter weigh balance.
Reagent and drug: glacial acetic acid is provided by Sinopharm Chemical Reagent Co., Ltd.；Its particle of compound wood Ni Zi, by
Xinjiang pharmaceutcal corporation, Ltd, Uygur provides, lot number: 1212522；Aspirin, by Huayin City, brocade future pharmaceutcal corporation, Ltd is mentioned
For lot number: A1111002.
2, method for preparation of drug:
Its particle (referred to as wooden Buddhist nun's particle in icon) of compound wood Ni Zi:
7.2g/kg: taking its particle of 18g compound wood Ni Zi, add 50ml pure water, sufficiently dissolves, 4 DEG C of preservations；
2.4g/kg: taking its particle of 6g compound wood Ni Zi, add 50ml pure water, sufficiently dissolves, 4 DEG C of preservations；
0.8g/kg: taking its particle of 2g compound wood Ni Zi, add 50ml pure water, sufficiently dissolves, 4 DEG C of preservations；
Comparison medicine aspirin: taking 250mg aspirin powder, add 50ml pure water, sufficiently dissolves, and 4 DEG C of refrigerators save.
0.6% acetic acid: taking 0.3ml glacial acetic acid, adds water constant volume to 50ml, mixes, and 4 DEG C of refrigerators save.
3, test method:
3.1 acetic acid writhing test
Mouse 40 are taken, be randomly divided into 5 groups: blank control group (Control), aspirin (ASP, 0.1g/kg) group are multiple
The high, medium and low dosage of its particle of lumps of wood Ni Zi (7.2,2.4,0.8g/kg) group will sufficiently be dissolved before experiment with water by test solution, be compareed
Group gives androgynous ponding, daily gastric infusion, and 1 time/d, continuous 7d.Respectively at 30min after the last administration, intraperitoneal injection 0.6%
Acetum 0.1ml/10g (acetum prepared before use).There is the writhing time for the first time and records in 15min to occur in observation
The number of writhing response (abdomen shrinks indent, stretches hind leg, and buttocks is raised, crawling).(such as table 1, Fig. 1)
Inhibiting rate %=(Control group writhing number-administration group writhing number)/Control group writhing number × 100
Writhing number in 1 mouse writhing response latency of table and 15min
Compared to the blank group compared with,*P < 0.05,**P < 0.01,***P < 0.001
Interpretation of result: its particle of compound wood Ni Zi can significantly reduce the intraperitoneal caused visceral layer of acetic acid injection and parietal layer abdomen
Film larger area, the inflammatory pain of long period are analyzed from writhing response incubation period first time, its particle of compound wood Ni Zi height,
In, low dosage compared to the blank group, middle and high dosage group has statistical difference compared to the blank group, to occurring pain for the first time
Time have extension effect；Writhing number is analyzed out of 15min, the compound wood high, medium and low dosage of its particle of Ni Zi and blank group phase
Than all having significant difference, showing that its particle of compound wood Ni Zi can effectively reduce mouse writhing number, and middle and high dosage
Effect is more obvious than low dosage effect.
3.2 hot plate method in mice
Take female mice several, first by only (temperature is adjusted to 55 ± 0.5 with YLS-6B intelligence hot-plate instrument before formal experiment
DEG C) screened.Mouse 1 is taken when screening every time, record mouse vola contacts hot plate, and (s, hot plate are anti-to metapedes required time is licked
Answer incubation period) it (is measured 2 times altogether, find out the average value of 2 measurements) as pain indicator, the response latency is first rejected greater than 30s
Or mouse slow in reacting or allergy less than 5s.Will the qualified animal of screening, be randomly divided into 5 groups: blank control group
(Control), aspirin (ASP, 0.1g/kg) group, the high, medium and low dosage of compound wood its particle of Ni Zi (7.2,2.4,0.8g/
Kg) group is sufficiently dissolved test drug with water before experiment, and Control group gives androgynous ponding, and daily gastric infusion 1 time/d, connects
Continuous 7d, measures pain threshold by above-mentioned Basic Pain Threshold value measuring method respectively at after the last administration 30,60,90,120min respectively, such as pain
Threshold is more than 60s, that is, stop test and based on 60s, in order to avoid scald foot.And its threshold of pain is calculated as follows and improves percentage.
Improve percentage (%) in the threshold of pain=[(average pain threshold before average pain threshold-administration after administration)/it is average before being administered
Pain threshold] × 100.It the results are shown in Table 2 and Fig. 2.
Influence of 2 compound wood Ni Zi its particle of table to the different time sections mouse threshold of pain and threshold of pain increase rate
P < 0.001 * P < 0.05 compared with Control group, * * P < 0.01, * * *
Interpretation of result: the action of its particle low dose group of compound wood Ni Zi is slower, does not mention in 30min, 60min and 90min
High mouse pain domain, but mouse can be improved to hot plate pain domain when acting on 120min；Its particle of compound wood Ni Zi is high, middle dose group is equal
Mouse pain domain (improving percentage > 50% in pain domain) can be significantly improved, and rapid-action, 30min shows analgesic activity, when continuing
Between it is longer, and as the extension of action time, analgesic activity have the tendency that enhancing, show good analgesic effect.
6, conclusion
Writhing assay caused by hot plate method and acetic acid is two kinds of common methods for being used for antalgesic primary dcreening operation, and hot plate method experiment is compared
The analgesic activity that suitable evaluation has maincenter to participate in, and acetic acid writhing test is relatively suitble to evaluation to have Peripheral Analgesic Effect mechanism drug
Screening.Acetic acid twisting experiment and mouse hot-plate are the experimental results showed that its particle of compound wood Ni Zi has a degree of central
And peripheral pain easing function.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
Centainly refer to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be any
One or more embodiment or examples in can be combined in any suitable manner.
Although an embodiment of the present invention has been shown and described, it will be understood by those skilled in the art that: not
A variety of change, modification, replacement and modification can be carried out to these embodiments in the case where being detached from the principle of the present invention and objective, this
The range of invention is defined by the claims and their equivalents.
Claims (4)
1. a kind of purposes of compound wood Ni Zi its pharmaceutical composition in medicine preparation, the drug is for inhibiting central and outer
Week property pain, its pharmaceutical composition of the compound wood Ni Zi are made of following raw material medicaments weight proportion: 50-150 parts of fennel root skin,
50-150 parts of peganum harmala L, 50-150 parts of anise fruit, 30-80 parts of chamomile, 30-80 parts of Herba Apii graveolentis root, witloof are 30-80 parts sub-, black
Kind grass seed 30-80 parts, 30-80 parts of cichory root, 30-80 parts of lemongrass, Dracocephalum moldavica be 30-80 parts sub-, 30-80 parts of Radix Glycyrrhizae, basil fruit 30-
80 parts and seed of hollyhock 30-80 parts.
2. purposes according to claim 1, which is characterized in that the bulk pharmaceutical chemicals weight proportion are as follows: 120 parts of fennel root skin,
120 parts of peganum harmala L, 120 parts of anise fruit, 60 parts of chamomile, 60 parts of Herba Apii graveolentis root, witloof sub 60 parts, 60 parts of fennelflower seed, witloof
60 parts of root, 60 parts of lemongrass, 60 parts of Dracocephalum moldavica, 60 parts of Radix Glycyrrhizae, 60 parts of basil fruit and 60 parts of seed of hollyhock.
3. purposes according to claim 1, which is characterized in that the dosage form of the drug is selected from injection, tablet, particle
One of agent, syrup, capsule, pill, oral solution, aerosol and spray.
4. purposes according to claim 1, which is characterized in that its pharmaceutical composition of the compound wood Ni Zi is with compound wood Buddhist nun
What the form of its diligent particle provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510629882.2A CN106540119B (en) | 2015-09-22 | 2015-09-22 | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510629882.2A CN106540119B (en) | 2015-09-22 | 2015-09-22 | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106540119A CN106540119A (en) | 2017-03-29 |
| CN106540119B true CN106540119B (en) | 2019-11-29 |
Family
ID=58364678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510629882.2A Active CN106540119B (en) | 2015-09-22 | 2015-09-22 | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106540119B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116474050A (en) * | 2023-05-04 | 2023-07-25 | 上海中医药大学 | Compound Munich Cuminum cyminum prescription and application of extraction part thereof in preventing and treating dysmnesia |
-
2015
- 2015-09-22 CN CN201510629882.2A patent/CN106540119B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 香青兰化学成分研究Ⅱ;古海锋等;《中国中药杂志》;20050531;第30卷(第9期);第677-679页，尤其是第677页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106540119A (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1970030A (en) | Chinese medicine for treating rheumatoid arthritis, preparation method and application thereof | |
| CN100382838C (en) | Chinese medicine for treating blood stagnation disease | |
| CN106540119B (en) | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN103610685A (en) | Traditional Chinese medicinal composition for treating dysmenorrhea | |
| CN106728145A (en) | It is a kind of to treat Chinese and western medicinal composition of acute diarrhea and preparation method thereof | |
| CN101804119B (en) | Traditional Chinese medicine preparation for treating thrombocytopenia and preparation method thereof | |
| CN102397326A (en) | Formula of Chinese angelica-motherwort herb decoction and preparation thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN101884756B (en) | Pharmaceutical composition with functions of expelling wind and removing dampness and activating collaterals and relieving pain, preparation method, preparation and application thereof | |
| CN110279691A (en) | A kind of surgical postoperative nursing analgesic and application thereof | |
| CN104013901A (en) | Medicament for treating pelvic inflammation | |
| CN103610741A (en) | Traditional Chinese medicinal composition for treating spermatorrhea | |
| Mahwi et al. | Hypoglycemic, antihistaminic and diuretic effects of aqueous extract of Adiantum capillus. | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN107281183B (en) | Analgesic composition | |
| CN106237250A (en) | A kind of Chinese medicine composition treating prostatic hyperplasia and capsule thereof and preparation method | |
| CN105194498B (en) | A kind of Chinese medicine composition and preparation method thereof for treating senile dementia | |
| CN105194352A (en) | Traditional Chinese medicine composition capable of improving learning and memory abilities and preparation method thereof | |
| CN105311065A (en) | Application of aleuritopteris argentea extract in preparation of medicines for treating cardiovascular and cerebrovascular diseases | |
| CN103611116A (en) | Traditional Chinese medicinal composition for treating vomiting of pregnancy | |
| CN104056244A (en) | Traditional Chinese medicine preparation for treating kidney stone | |
| CN102920969A (en) | Traditional Chinese medicine compound preparation for treating vasculitis, ischialgia and spondylitis, and preparation method thereof | |
| CN1256137C (en) | Chinese medicine for treating pulmonary fuberculosis | |
| CN102266444A (en) | Medicament for treating anaphylactoid purpura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Use of compound maniz and its pharmaceutical composition in the preparation of analgesic drugs Effective date of registration: 20220715 Granted publication date: 20191129 Pledgee: Tongda sub branch of Bank of Urumqi Co.,Ltd. Pledgor: XINJIANG UYGUR PHARMACEUTICAL CO.,LTD. Registration number: Y2022650000027 |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yin Qiang Inventor after: Wang Changhong Inventor after: Mu Dandan Inventor after: Yin Hailong Inventor after: Liu Lacai Inventor after: Cheng Xuemei Inventor after: Cheng Juanjuan Inventor after: Liu Zijia Inventor after: Nura River. Paholdin Inventor before: Yin Qiang Inventor before: Liu Zijia Inventor before: Nura River. Paholdin Inventor before: Wang Changhong Inventor before: Mu Dandan Inventor before: Ma Xuan Inventor before: Yin Hailong Inventor before: Liu Lacai Inventor before: Cheng Xuemei Inventor before: Cheng Juanjuan Inventor before: Huang Lu |